Endocrinology

Top Story

FDA approves Freestyle Libre Pro CGM system

October 1, 2016

The FDA has approved Abbott’s FreeStyle Libre Pro, a continuous glucose monitoring system for health care providers to use with their patients with diabetes, the company announced in a press release.

The FreeStyle Libre Pro system is part of Abbott's FreeStyle family of products, including the sensing technology for consumers, the FreeStyle Libre system. The sensor continuously measures glucose in interstitial fluid through a small (5 mm long, 0.4 mm wide) filament that is inserted just under the skin. The device records glucose levels every 15 minutes, capturing up to 1,340 glucose results for up to 14 days, giving the treating provider comprehensive data for a complete glycemic profile of the patient.

Meeting News Coverage

Top 5 stories from ATA 2016

September 30, 2016
Endocrine Today has compiled a list of the top five thyroid stories posted online to come from the Annual Meeting of the American Thyroid Association in Denver. …
In the Journals

Elevated waist-to-height ratio associated with pediatric psoriasis

September 30, 2016
Children with psoriasis were more likely to have elevated waist-to-height ratios compared with those with noninflammatory skin conditions, while the two cohorts did not…
In the Journals Plus

Nighttime hot flashes, sleep disruption linked to mild depression in estrogen-deprived women

September 30, 2016
Healthy, premenopausal women exposed to a temporary decline in estradiol were more likely to experience mild depressive symptoms if they perceived nighttime hot flashes…
In the Journals Plus

Sex hormones fail to influence all-cause, CVD mortality in middle-aged men

September 30, 2016
Mortality and cardiovascular disease outcomes are not influenced by testosterone, dihydrotestosterone or estradiol in predominantly middle-aged men, study data show. …
More News Headlines »
CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Video
Meeting News Coverage

VIDEO: Empagliflozin significantly reduces microvascular outcomes

September 16, 2016
More »
Featured
ATA 2016

ATA 2016

CME Video

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic…
More »
in the journals

Get the best of the journals.
Read abstracts, search and filter results, gain perspective, view graphics.

Go »
Current Issues
View the Current Issues
morganatic-roan
morganatic-roan